| Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations |
33 |
| The Role of the Milan System for Reporting Salivary Gland Cytopathology: A 5-Year Institutional Experience |
26 |
| Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients |
25 |
| Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas |
24 |
| A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma |
23 |
| The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC): An International Effort Toward Improved Patient Care-When the Roots Might Be Inspired by Leonardo da Vinci |
21 |
| Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay |
19 |
| Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy |
17 |
| Moray micro forceps biopsy improves the diagnosis of specific pancreatic cysts |
16 |
| Insulinoma-associated protein 1 is a sensitive and specific marker of neuroendocrine lung neoplasms in cytology specimens |
16 |
| Application of the Milan System for Reporting Submandibular Gland Cytopathology: An international, multi-institutional study |
15 |
| Molecular Testing for Indeterminate Thyroid Nodules: Performance of the Afirma Gene Expression Classifier and ThyroSeq Panel |
14 |
| Strategies for Screening and Early Detection of Anal Cancers: A Narrative and Systematic Review and Meta-Analysis of Cytology, HPV Testing, and Other Biomarkers |
14 |
| Northern Italy in the American South: Assessing interobserver reliability within the Milan System for Reporting Salivary Gland Cytopathology |
13 |
| Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology |
13 |
| Implementing The Paris System for Reporting Urinary Cytology results in a decrease in the rate of the atypical category and an increase in its prediction of subsequent high-grade urothelial carcinoma |
13 |
| Immunocytochemistry for predictive biomarker testing in lung cancer cytology |
12 |
| One year of experience using the Paris System for Reporting Urinary Cytology |
12 |
| Benign call rate and molecular test result distribution of ThyroSeq v3 |
11 |
| Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): Implications for the risk of malignancy (ROM) in the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) |
11 |
| Analysis of Histologic Follow-Up and Risk of Malignancy for Salivary Gland Neoplasm of Uncertain Malignant Potential Proposed by the Milan System for Reporting Salivary Gland Cytopathology |
11 |
| Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations |
11 |
| Risk of Malignancy Associated With Cytomorphology Subtypes in the Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP) Category in the Milan System: A Bi-Institutional Study |
11 |
| Suspicious salivary gland FNA: Risk of malignancy and interinstitutional variability |
10 |
| Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules |
10 |
| Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience |
9 |
| Diagnostic challenges and problem cases in salivary gland cytology: A 20-year experience |
8 |
| Ancillary Testing in Salivary Gland Cytology: A Practical Guide |
8 |
| Use of the Thyroid Imaging, Reporting, and Data System (TI-RADS) Scoring System for the Evaluation of Subcentimeter Thyroid Nodules |
8 |
| Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+in triage of women with minor abnormal cytology |
8 |
| Improved Correlation of Urinary Cytology Specimens Using The Paris System in Biopsy-Proven Upper Tract Urothelial Carcinomas |
8 |
| Simultaneous detection of single-nucleotide variant, deletion/insertion, and fusion in lung and thyroid carcinoma using cytology specimen and an RNA-based next-generation sequencing assay |
7 |
| Comparison of cytocentrifugation supernatant fluid and formalin-fixed paraffin-embedded tissue for targeted next-generation sequencing |
7 |
| Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens |
7 |
| Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens |
7 |
| Subtyping salivary gland neoplasm of uncertain malignant potential based on cell type demonstrates differential risk of malignancy |
7 |
| Ancillary Studies in Pleural, Pericardial, and Peritoneal Effusion Cytology |
7 |
| Biomarkers for immune checkpoint inhibitors: The importance of tumor topography and the challenges to cytopathology |
6 |
| FNA cytology of solitary fibrous tumors and the diagnostic value of STAT6 immunocytochemistry |
5 |
| HPV-associated neuroendocrine carcinomas of the head and neck in FNA biopsies: Clinicopathologic features of a rare entity |
5 |
| A 20-year and 000-specimen journey to Paris reveals the influence of reporting systems and passive peer feedback on pathologist practice patterns |
5 |
| CytoLyt fixation significantly inhibits MIB1 immunoreactivity whereas alternative Ki-67 clone 30-9 is not susceptible to the inhibition: Critical diagnostic implications |
5 |
| Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry |
5 |
| Diagnostic accuracy of FNA cytology for diagnosis of salivary gland tumors in pediatric patients |
5 |
| Cytologic evaluation of p16 staining in head and neck squamous cell carcinoma in CytoLyt versus formalin-fixed material |
5 |
| Improved Diagnostic Precision of Urine Cytology by Implementation of The Paris System and the Use of Cell Blocks |
5 |
| Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer |
5 |
| NKX2.2 immunohistochemistry in the distinction of Ewing sarcoma from cytomorphologic mimics: Diagnostic utility and pitfalls |
5 |
| Reducing DNA damage by formaldehyde in liquid-based cytology preservation solutions to enable the molecular testing of lung cancer specimens |
5 |
| Performance of an artificial intelligence algorithm for reporting urine cytopathology |
5 |
